Transcranial Magnetic Stimulation (TMS) Safety with Respect to Seizures: A Literature Review
Open Access
- 1 December 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Neuropsychiatric Disease and Treatment
- Vol. ume 16, 2989-3000
- https://doi.org/10.2147/ndt.s276635
Abstract
Transcranial magnetic stimulation is an increasingly popular FDA-approved treatment for resistant depression, migraines, and OCD. Research is also underway for its use in various other psychiatric and medical disorders. Although rare, seizures are a potential adverse event of TMS treatment. In this article, we discuss TMS-related seizures with the various coils used to deliver TMS, the risk factors associated with seizures, the differential diagnosis of its presentations, the effects of sleep deprivation and alcohol use on seizures, as well as seizure risks with protocols for traditional TMS, theta-burst stimulation, and accelerated TMS. A discussion is presented comparing the potential risk of seizures with various psychotropic medications versus TMS. Included are case reports of TMS seizures in the child/adolescent patient, bipolar disorder patients, patients with a history of a traumatic brain injury, and those with epilepsy. Reports are also shared on TMS use without seizures in patients with a history of head injuries and TMS’s continued use if patients have a seizure during their TMS treatment. Findings generated in this review suggest the following. Seizures, if present, are usually self-limiting. Most treatment recommendations for TMS-related seizures are supportive in nature. The risk of TMS-related seizures is < 1% overall. TMS has successfully been used in patients with epilepsy, traumatic brain injuries, and those with a prior TMS-related seizure. The rate of TMS-related seizures is comparable to that of most psychotropic medications. While having a seizure is a rare but serious adverse effect of TMS, the benefits of treating refractory depression with TMS may outweigh the risk of suicidal ideation and other significant complications of depression.Keywords
This publication has 64 references indexed in Scilit:
- 166 Post Market Rate of Seizures During TMS Treatment with NeuroStar® System Appears to Be Lower than Previously EstimatedCNS Spectrums, 2020
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)Clinical Neurophysiology, 2020
- Accelerated TMS for Depression: A systematic review and meta-analysisPsychiatry Research, 2018
- Rate of inadvertently induced seizures with deep repetitive transcranial magnetic stimulationBrain Stimulation, 2018
- Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of DepressionBritish Journal of Psychology, 2018
- THETA-BURST STIMULATION: A NEW FORM OF TMS TREATMENT FOR DEPRESSION?Depression and Anxiety, 2014
- Repeated sessions of sub-threshold 20-Hz rTMS. Potential cumulative effects in a brain-injured patientClinical Neurophysiology, 2012
- TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICEDepression and Anxiety, 2012
- Safety of Theta Burst Transcranial Magnetic Stimulation: A Systematic Review of the LiteratureJournal of Clinical Neurophysiology, 2011
- Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and researchClinical Neurophysiology, 2009